



## Drugs with glutamate-based mechanisms of action in psychiatry

Adrian Andrzej Chrobak<sup>1</sup> · Marcin Siwek<sup>2</sup>

Received: 4 August 2024 / Revised: 13 September 2024 / Accepted: 16 September 2024 / Published online: 27 September 2024  
© The Author(s) 2024

### Abstract

Psychopharmacotherapy of major psychiatric disorders is mostly based on drugs that modulate serotonergic, dopaminergic, or noradrenergic neurotransmission, either by inhibiting their reuptake or by acting as agonists or antagonists on specific monoamine receptors. The effectiveness of this approach is limited by a significant delay in the therapeutic mechanism and self-perpetuating growth of treatment resistance with a consecutive number of ineffective trials. A growing number of studies suggest that drugs targeting glutamate receptors offer an opportunity for rapid therapeutic effect that may overcome the limitations of monoaminergic drugs. In this article, we present a review of glutamate-modulating drugs, their mechanism of action, as well as preclinical and clinical studies of their efficacy in treating mental disorders. Observations of the rapid, robust, and long-lasting effects of ketamine and ketamine encourages further research on drugs targeting glutamatergic transmission. A growing number of studies support the use of memantine and minocycline in major depressive disorder and schizophrenia. Amantadine, zinc, and *Crocus sativus* extracts yield the potential to ameliorate depressive symptoms in patients with affective disorders. Drugs with mechanisms of action based on glutamate constitute a promising pharmacological group in the treatment of mental disorders that do not respond to standard methods of therapy. However, further research is needed on their efficacy, safety, dosage, interactions, and side effects, to determine their optimal clinical use.

**Keywords** Excitotoxicity · Psychosis · Mood disorders · Treatment resistance · Antidepressant drugs · Antipsychotic drugs

### Abbreviations

AA	Arachidonic acid	HCN	Hyperpolarization-activated cyclic nucleotide-gated channel
AMPA	Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor	iGluR	Ionotropic glutamate receptor
BD	Bipolar disorder	MAO	Monoamine oxidase
BDNF	Brain-derived neurotrophic factor	MDD	Major depressive disorder
CANMAT	Canadian Network for Mood and Anxiety Treatments	MIPS	Myo-inositol phosphate
cPLA2	Cytosolic phospholipase A2	mGluR	Metabotropic glutamate receptor
CNS	Central nervous system	NMDAR	N-methyl-D-aspartate receptor
CoA	Coenzyme A	OCD	Obsessive-compulsive disorder
COX	Cyclooxygenase	PCP	Phencyclidine
D	Dopamine	PD-L1	Programmed cell death protein 1 ligand
DAT	Dopamine transporter	SZ	Schizophrenia
GABA	Gamma-aminobutyric acid	TRD	Treatment-resistant depression
		MADRS	Montgomery-Åsberg Depression Rating Scale
		EAAT	2-Excitatory Amino Acid Transporter 2

✉ Marcin Siwek  
marcin.siwek@uj.edu.pl

<sup>1</sup> Department of Adult Psychiatry, Jagiellonian University Medical College, Kopernika 21A, 31-501 Kraków, Poland

<sup>2</sup> Department of Affective Disorders, Jagiellonian University Medical College, Kopernika 21A, 31-501 Kraków, Poland

## Introduction

Psychopharmacotherapy of affective and other mental disorders is mostly based on drugs that modulate serotonergic, dopaminergic, or noradrenergic neurotransmission, either by inhibiting reuptake or by acting as agonists or antagonists on specific monoamine receptors [1]. Treatment based on the abovementioned mechanisms has many limitations. Firstly, it is associated with a significant delay of the therapeutic effect, and secondly, it is not effective in the case of drug resistance, as the application of subsequent pharmacological strategies, based on the same mechanisms, results in decreasing efficacy with each therapy cycle and may exacerbate the drug resistance by inducing adaptive changes in the synapses [2–4]. A solution to the abovementioned problems is the development of drugs that target glutamatergic neurotransmission [5]. Especially in the case of depressive disorders, drugs targeting glutamate receptors (such as ketamine, which is a prototypical example) offer an opportunity for a rapid therapeutic effect and overcoming drug resistance, with minimal risk of adverse effects generated by conventional drugs [5]. Modulation of glutamatergic receptor activity is also used to augment classical antidepressant treatment (e.g. by adding esketamine, zinc, minocycline, or amantadine) [5]. Some plant-derived compounds - e.g. safranal also affect the activity of glutamatergic receptors, which results in antidepressant or anxiolytic effects [6, 7]. Apart from affective disorders, it has been shown that drugs targeting glutamate receptors, such as memantine, can improve the outcomes of treatment of obsessive-compulsive disorders (OCD) or schizophrenia (SZ), enhancing the action of other drugs [8–12]. Additionally, some mood stabilizers, such as lamotrigine or valproic acid, alongside many other complex mechanisms, exert their action by modifying glutamatergic neurotransmission. In this article, we aim to conduct a PubMed review of selected glutamate-modulating drugs that are already used in psychiatric practice or are at the stage of advanced clinical trials. We will discuss their mechanism of action, as well as preclinical and clinical studies of their efficacy in treating mental disorders.

## Glutamate receptors

Glutamate is the predominant excitatory neurotransmitter in the human central nervous system, which plays a vital role in synaptic plasticity, including long-term potentiation [13, 14]. Glutamate receptors are classified into two types: ionotropic glutamate receptors (iGluRs)

and metabotropic glutamate receptors (mGluRs). iGluRs consist of N-methyl-D-aspartate receptor (NMDAR),  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and kainite receptors. mGluRs are divided into three groups (I, II, and III) [13]. NMDAR is a tetrameric ion channel that consists of two essential GluN1 subunits along with two others, which can either be GluN2 or GluN3 [15]. Activation of this receptor requires bindings of either two glycine or d-serine molecules (acting as co-agonists) to its GluN1 subunits, plus two glutamate molecules to its GluN2 subunit [15]. NMDAR is functionally paired with AMPAR [16]. Activation of the latter causes cell depolarization, which results in the displacement of the  $Mg^{2+}$  ion from the NMDAR pore and the subsequent entry of  $Ca^{2+}$  and  $Na^{+}$  ions into the neurons [16]. An elevated intracellular  $Ca^{2+}$  concentration is essential for the proper functioning and structural integrity of neurons [17]. However, in pathological circumstances, excessive influxes of  $Ca^{2+}$  in neuronal deterioration or death [17]. This phenomenon, referred to as excitotoxicity is a key pathophysiological mechanism of neurodegeneration in major psychiatric disorders [18]. There is an increasing amount of research suggesting that altered glutamatergic neurotransmission emerges as a vital pathophysiological event related to etiopathogenesis of mental disorders such as SZ, OCD, bipolar disorder (BD), and major depressive disorder (MDD), encompassing instances of treatment-resistant depression (TRD) [18].

## Ketamine and (S)-ketamine

Ketamine is a drug with a long history in anesthetic practice spanning approximately six decades that has demonstrated a notably promising profile as an antidepressant over the last twenty years [19]. The main mechanism of action of this drug relies on non-competitive inhibition of NMDAR, coupled with enhanced stimulation of AMPAR [5]. It is hypothesized that antidepressant effect of this substance is related to the cascade of events related to glutamatergic disinhibition [5]. Through rapid blockade of NMDAR, ketamine inhibits GABAergic interneurons responsible for tonic inhibition of cortical glutamatergic neurons [5]. Increased release of glutamate by these cells activates AMPAR, leading to an influx of  $Ca^{2+}$  and initiation of  $Ca^{2+}$ -dependent processes, which result in increased synthesis and release of brain-derived neurotrophic factor (BDNF). Finally, BDNF induces intracellular pathways mediated by the mammalian target of rapamycin (mTOR) and extracellular regulated kinase (ERK). Those processes lead to increased synthesis of synaptic proteins resulting in long-lasting neurostructural and neurofunctional changes [5].

A meta-analysis has shown that in TRD, even a single dose of ketamine can induce a rapid and robust

antidepressant effect lasting up to seven days [20]. The network meta-analysis of 31 randomized controlled trials has shown that two weeks after the initiation of the treatment, ketamine was ranked first among twelve pharmacological and two somatic interventions for TRD, reaching a 14-fold response rate versus placebo [20]. Noteworthy, within 40–240 min after the first administration, ketamine induces a significant reduction of suicidal ideation that lasts up to one week. Repeated administration of this drug has been shown to completely alleviate suicidal ideation in 69% of TRD patients [21].

Although most patients experience symptom improvement for several weeks following a single ketamine infusion, a substantial number of patients present recurrence of depressive symptoms [22]. About one-fourth of those who achieved remission 72 h after the first dose, relapses within seven days post-infusion, and another fourth after the end of the second week [22]. Therefore, despite the significant effectiveness of this drug, the necessity of its administration through repeated intravenous infusions limits the possibility of its use in long-term therapy. Studies have shown that the S (+) enantiomer of ketamine (esketamine), which can be applied in the form of nasal spray, demonstrates similar efficacy and safety pattern in the treatment of TRD patients [23]. A randomized double-blind active-controlled study has shown that esketamine administered twice weekly presented a clinically meaningful effect during the second day of treatment that persisted after four weeks of trial [24]. Improvement of depressive symptoms has been shown to persist 2 months after the cessation of esketamine dosing [25]. A growing number of studies demonstrates that esketamine is safe and effective add-on to antidepressant treatment of TRD resulting in significant increase of remission rates in this clinical group [26]. The discovery that NMDAR antagonists may induce rapid onset and long-lasting antidepressant effects is a breakthrough in the modern psychopharmacotherapy, that has led to increased interest in the use of glutamatergic compounds in the treatment of major psychiatric disorders [5, 18].

## Memantine

Memantine is a low affinity, noncompetitive NMDAR antagonist that can easily cross the blood-brain barrier that is primarily used in treatment of dementia [27]. Preclinical studies demonstrated that this drug poses antidepressant activity attributed to BDNF upregulation, mitochondrial protection and anti-neuroinflammatory properties [28, 29]. A recent comprehensive systematic review and meta-analysis of 11 randomized controlled trials involving MDD, BD and SZ patients showed that memantine, primarily as an add-on treatment, notably outperformed placebo in reducing severity of depressive symptoms in mood disorders [12].

Growing number of clinical studies indicate that memantine appears to be safe and well tolerated treatment option for SZ symptoms [8]. Considering hypothesis of NMDAR hypofunction in SZ, it is controversial why memantine treatment does not yield severe side effects like other NMDAR antagonists such as ketamine or phencyclidine (PCP) [22]. It is hypothesized that memantine inhibits NMDAR based on combination of fast unblocking kinetics and strong functional voltage dependency [8]. Under physiological conditions, NMDARs are activated only by high concentration of glutamate that coincide with strong neuronal depolarisation, which is required to remove  $Mg^{2+}$  from their channel pores [8]. However, under pathological conditions, even a moderate depolarization can dislodge  $Mg^{2+}$  and allow longer stimulation, by lower glutamate concentrations [8]. While PCP reveals a high affinity to NMDAR in both physiological and pathological conditions, memantine binds weakly to these receptors in a voltage-dependent manner [8]. Memantine inhibits NMDAR only in a state of moderate depolarization, thus it prevents its prolonged activation under pathological conditions [8]. During strong depolarisation memantine quickly unblocks NMDAR channel pores, which suggest its minimal impact on physiological glutamatergic transmission and corresponds with the good tolerability and safety profile of this drug (for detailed review [8]). Meta-analysis of eight randomized, double-blind, placebo-controlled trials showed that adjunctive memantine is an effective and safe intervention for improving cognitive deficits and negative symptoms in SZ [30]. Hassanpour et al. 2019 have shown that eight weeks of memantine add-on treatment improved verbal memory, working memory, learning, phonological fluency, and learning without the effect on psychotic symptoms in the chronic SZ patients' group [10]. Veerman et al. 2016 performed a randomized, double-blind placebo-controlled study of memantine augmentation in clozapine-refractory SZ [31]. When compared to the placebo group, twelve weeks of memantine treatment was associated with improved verbal and visual memory and negative symptoms [31]. The authors hypothesized that the synergistic effects of those drugs may stem from their collective impact on NMDAR [31]. While clozapine increases the expression of both AMPAR and NMDAR [32, 33], memantine can promote additional up-regulation of NMDAR, which results in stronger neuronal activation when presented with robust stimuli [34]. This mechanism may facilitate the induction of long-term potentiation and improve cognitive functioning [31]. Given the fact that 30–50% of SZ patients do not respond to at least two subsequent antipsychotic drugs and up to 70% of patients treated with clozapine reach only partial response, there is a vital need to seek new strategies to overcome treatment resistance in this clinical

group [35, 36]. The abovementioned studies demonstrate that memantine yields the potential to improve cognitive and negative symptoms in treatment-resistant SZ.

A growing number of studies indicate that excessive glutamatergic activity, elevated glutamate levels in cerebrospinal fluid, and gene polymorphisms coding for the NMDAR may play a significant role in the pathophysiology of OCD [9, 11, 37–39]. A meta-analysis of eight clinical studies has shown that eight weeks of memantine augmentation to first-line pharmacological treatment resulted in a significant reduction of OCD symptoms (mean reduction of 11.73 points on the Yale-Brown Obsessive-Compulsive Scale) [11]. Further analyses of four double-blind placebo-controlled trials revealed that patients receiving memantine had up to a 3.61-fold higher response rate than the placebo group [11]. Memantine augmentation has been proposed as an intervention for selective serotonin reuptake inhibitors-resistant OCD or BD patients who exhibit contradiction to the use of first-line treatment [11].

## Minocycline

Minocycline is a tetracycline antibiotic that effectively penetrates the blood-brain barrier and demonstrates significant neuroprotective properties [40]. This drug has been shown to inhibit nitric oxide synthesis, suppress proinflammatory activity of microglia, and reduce apoptosis [41–44]. A growing number of studies indicate this drug may directly affect glutamatergic transmission [43, 45, 46]. Recently it has been proposed that minocycline positively modulates GluR1 subunit receptors of AMPA leading to the BDNF upregulation [46, 47]. While this drug does not present direct interactions with NMDAR it has been shown that minocycline can attenuate glutamate-induced  $\text{Ca}^{2+}$  influx and prevent neuronal death caused by excitotoxicity [46]. Clinical and animal studies suggest that the abovementioned mechanisms may be related to the broad effects of this drug in the treatment of SZ and MDD [46]. Minocycline has outperformed placebo in the reduction of depressive symptoms in the groups HIV positive patients and TRD group, as well as in the improvement of global functioning scores in MDD [48–50]. However, recent studies did not replicate those findings [49]. Hellmann-Regen et al. (2022) have performed a multicentre double-blind randomized clinical trial of 200 mg minocycline as an add-on to antidepressant treatment in MDD of throughout six weeks with a six-month follow-up [51]. In the group of 173 participants, the drug did not alter the severity depressive of depressive symptoms [51]. The discrepancy between the abovementioned studies may be partially explained by the observation that minocycline efficacy is mediated by the baseline inflammatory state [52]. In a double-blind double-blind randomized clinical trial, it has been shown that minocycline responders presented

increased serum concentration of IL-6 and low-grade inflammation defined as  $\text{CRP} \geq 3 \text{ mg/l}$  [52]. Thus, the antidepressant effect of minocycline may be restricted to depression which is associated with increased inflammation [52].

Clinical studies evaluating the efficacy of minocycline add-on treatment to both typical and atypical antipsychotics reveal improvement in the wide spectrum of SZ symptoms [46, 53, 54]. In a double-blind, randomized placebo-controlled study, Levkovitz et al. (2010) have shown that minocycline augmentation of antipsychotic treatment in the group of early SZ patients resulted in significant improvement of negative symptoms and executive functions [54]. In an open-label study, minocycline add-on to atypical antipsychotic drugs resulted in approximately 40% reduction of both positive and negative symptoms, and a 50% decrease in general psychopathology measured by PANS after four weeks of the treatment [53]. Those results suggest that minocycline yields the potential to ameliorate positive, negative, and cognitive symptoms in SZ.

## Zinc

Zinc serves as an essential cofactor of many proteins and plays a crucial role in the processes of DNA replication, transcription, protein synthesis, maintaining cell membrane integrity, and immune system regulation [55]. This ion is a vital component of the antioxidative mechanisms responsible for the stabilization of the blood-brain barrier and neuronal survival [56, 57]. Zinc has been shown to play a significant role in the pathophysiology of depression, related to its modulatory effect on glutamatergic transmission and synaptic plasticity [58]. Zinc is a potent regulator and inhibitor of the NMDAR, an antagonist of mGluR1 and 2 receptors, and an enhancer of AMPAR activity [59]. Its deficiency leads to overactivity and upregulation of NMDAR posing a threat of excitotoxicity [59] and it is related to the occurrence of depressive symptoms [57].

Antidepressant properties of zinc have been shown in both clinical and animal studies. This trace element was found to be active in various models of depressive-like behavior, such as the tail suspension test, the forced swim test, and chronic unpredictable stress, olfactory bulbectomy, and chronic mild stress [60–62]. Moreover, zinc administration has been shown to enhance the antidepressant effect of citalopram and imipramine [56, 60, 61]. In our placebo-controlled study zinc supplementation potentiated imipramine treatment leading to a significant reduction of depressive symptoms in TRD, but not in the group of non-resistant MDD patients [63]. Another placebo-controlled, double-blind trial demonstrated that after six and twelve weeks of zinc add-on treatment to tricyclic antidepressants or selective serotonin reuptake inhibitors led to a significant

reduction of depressive symptoms measured with the use of the Hamilton Depression Rating Scale and Beck Depression Inventory [63]. This effect has been replicated in further studies in MDD [64, 65].

## Crocus sativus

Saffron (*Crocus sativus*) is a commonly used herb for coloring and flavoring food. It has been suggested that this herbal supplement possesses an antidepressant effect associated with its impact on the monoaminergic system [6, 66, 67]. Two of its major bioactive compounds, which are crocin and safranal may inhibit reuptake of serotonin, dopamine, and norepinephrine [66]. Saffron ' effects may be also mediated by their interactions with the glutamatergic system. Acute administration of safranal reduced kainic acid-induced elevation of glutamate transmission in rat hippocampus [68]. Moreover, Saffron extracts decreased glutamatergic signalization in rat cortical slices [69] which suggests that this substance may ameliorate the excessive release of this neurotransmitter. A preclinical study has shown that safranal, crocins, and crocetin may have depressive-like symptoms in mice measured in forced swim tests [70, 71]. Meta-analysis of five randomized clinical trials has shown that saffron supplementation was superior to placebo in the reduction of depressive symptoms [72]. Short-term six-week studies have demonstrated that there are no significant differences between saffron and imipramine or fluoxetine in MDD patients [72–74]. However, it should be noted that all of the abovementioned studies were single-centre trials organized within the same clinical settings in Iran, which indicates a need for more multisite studies [72]. Further randomized placebo-controlled clinical trials have shown that saffron as well as mixed saffron/curcumin preparations are superior to placebo in ameliorating depressive symptoms in MDD [67, 75]. In a group of older MDD patients, saffron has revealed an antidepressant effect comparable to sertraline [76]. More large-sample, multisite, and long-term clinical trials are needed to clarify saffron's potential role in MDD treatment [72]. Despite the methodological limitations of these studies, the Canadian Network for Mood and Anxiety Treatments (CANMAT) enlisted saffron as a third-line option of so-called “complementary and alternative medicine treatments” [77]. Based on the observations that saffron extracts may limit excessive glutamatergic transmission, it has been suggested that this herbal medicine may be effective in the treatment of SZ [78]. Animal studies have reported that acute supplementation with crocins improved the schizophrenia-like negative symptoms induced by subchronic treatment with ketamine [78]. Interestingly, this intervention has also decreased the severity of ataxia symptoms, which are observed in SZ patients [79, 80]. Currently,

there is only one double-blind placebo-controlled study that analyzed the effects of saffron extracts and crocin in SZ [81]. However, this trial evaluated only the safety and tolerability of those substances but did not include any efficacy measures [81]. Therefore, there is no data indicating the validity of using saffron for the treatment of SZ symptoms [81].

## Amantadine

Amantadine is a drug primarily known for its use in the treatment of type A influenza virus and dyskinesia associated with parkinsonism, but a growing number of studies indicate the potential use of this drug in the therapy of mental disorders, especially in affective disorders [82–85]. Amantadine may reduce the severity of depressive symptoms by increasing dopaminergic transmission through the inhibition of dopamine transporters (DAT), monoamine oxidase B (MAO-B), and agonistic effect on D<sub>1</sub> [83, 86, 87]. Moreover, this drug may potentially exert antidepressant effects through noncompetitive inhibition of NMDAR, which can both enhance the inhibition of DAT and induce effects like those of esketamine and ketamine [83, 86, 87]. Rogóz et al. 2007 have shown that amantadine exerts a significant antidepressant effect which may be used in the treatment of TRD [84]. Amantadine augmentation to ongoing imipramine therapy resulted in significant improvement of depressive symptoms (68% of responses and partial responses) after six months of joint treatment [84]. Krzystanek et al. 2023 presented the possibility of using this drug in the treatment of dysthymia [84]. In a naturalistic case series study, amantadine has been shown to be an effective and well-tolerated drug associated with quick improvement of depressive symptoms and persistency of the therapeutic effect after the discontinuation of the treatment [83]. The effectiveness of this therapy was comparable to sertraline [83]. Another study of this group has demonstrated the utility of amantadine as an add-on therapy for treatment-resistant bipolar depression [85]. In the series of four patients, it has been shown that the use of this drug resulted in rapid improvement of depressive symptoms after one week of treatment without the switch of the phase [85]. This effect persisted even when the drug was discontinued two weeks after the antidepressant effect was achieved [85]. In the retrospective chart review, Morrow et al. 2021 evaluated the utility of amantadine for the treatment of childhood and adolescent psychiatric symptoms in the group of 297 pediatric patients with a variety of clinical diagnoses (attention deficit hyperactivity disorder, conduct disorder, depressive disorder, anxiety disorder, autism spectrum disorder, post-traumatic stress disorder, intellectual disability) [88]. Amantadine treatment was effective in improving impulsivity, irritability, anger, and concentration [88]. Therapy with this drug enabled discontinuation of antipsychotic or antidepressant drugs in 42% and 28% of patients [89],

respectively [88]. Abovementioned results indicate the need for randomized controlled clinical trials evaluating the utility of the amantadine in the treatment of mental disorders.

### Antiseizure medications

Due to their significant mood-stabilizing effect, antiseizure medications have a wide range of applications in the treatment of mental disorders [90]. Those drugs are commonly used as normothermic medication for acute manic states (carbamazepine and valproate), acute bipolar depression (lamotrigine), and in long-term prevention of affective episodes (carbamazepine, valproate, and lamotrigine) in BD [89, 91, 92]. In terms of MDD, a meta-analysis of eight double-blinded randomized controlled trials has shown that lamotrigine augmentation of antidepressant treatment results in a significant reduction of depressive symptoms in TRD [93]. Topiramate is an antiseizure drug with a complex mechanism involving AMPAR and kainite receptor inhibition [94]. A recent meta-analysis confirmed that topiramate significantly reduces both binge eating frequency and weight in patients with binge eating disorder [94]. In the case of SZ, adjunctive use of this drug to antipsychotic medication has been shown to significantly improve positive, negative, and general symptoms as well as resulted in weight reduction [95]. Each of the above-mentioned drugs significantly affects the glutamatergic system. The description of these mechanisms is presented in Table 1.

### NMDA glycine site partial agonists

Rapastinel is a novel glutamatergic drug that acts as an agonist of the NMDAR glycine site [96]. Preclinical studies have shown that a single dose of rapastinel evoked antidepressant-like and procognitive effects that lasted for one week [97]. This activity has been linked with the NMDAR agonism and induction of NMDAR-dependent plasticity akin to long-term potentiation [96]. In a single double-blind, randomized, placebo-controlled study in a group of 116 TRD patients, a single injection of rapastinel significantly reduced depressive symptoms within two hours with an effect that lasted for seven days [98].

Apimostinel is a novel, selective modulator of NMDAR that presents several thousand-fold more potent than rapastinel at the glycine site [99]. Currently, the efficacy of intravenous and oral formulations of this drug is evaluated in phase II trial for MDD and phase I trial in healthy individuals, respectively [99].

### N-acetylcysteine

N-acetylcysteine (NAC) is commonly used as an antioxidant precursor to glutathione ( $\gamma$ -glutamylcysteinylglycine; GSH)

which is used in the treatment of a wide range of medical conditions such as chronic obstructive pulmonary disease, paracetamol overdose and contrast-induced nephropathy [100]. A growing number of studies have pointed out that NAC may have a beneficial effect on several pathophysiological processes observed in major psychiatric disorders, such as neuroinflammation, disrupted glutamate neuronal activity, altered neurogenesis, oxidative stress, and increased apoptosis [101–103]. Clinical studies point out that NAC may improve psychopharmacotherapy outcomes in SZ [104]. Meta-analysis of 11 double-blind randomized placebo-controlled studies presented that this drug outperformed the placebo in ameliorating positive and negative symptoms, as well as deficits of attention and working memory in SZ patient groups [104]. In the case of affective disorders results of clinical trials are less encouraging. Systematic reviews and meta-analyses of double-blind randomized placebo-controlled trials pointed out that adjunctive treatment with the use of NAC has no beneficial effects in bipolar depression [105, 106], MDD [106] as well as on depressive symptoms in SZ patients groups [104].

### Basimglurant

Basimglurant is a novel, selective, negative allosteric modulator of mGluR5 that does not demonstrate pharmacological activity on monoamine reuptake transporters [107]. It is hypothesized that this drug leads to the preferential inhibition of mGluR5 in the subpopulation of cortical limbic GABA interneurons resulting in the disinhibition of glutamatergic networks in brain circuits related to mood regulation [108]. Preclinical studies indicated that basimglurant reduces the severity of depressive-like symptoms measured in forced swim test procedures and normalizes anhedonia index in animal models of anhedonia [107]. In a six-week-long double-blind placebo-controlled randomized clinical trial of 333 MDD patients, basimglurant did not differ in terms of the primary endpoint (mean change in clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS) score) [109]. However secondary and exploratory endpoint analyses demonstrated that this drug outperformed the placebo in the case of patient-rated measures of depressive symptoms (Quick Inventory of Depressive Symptomatology Self-Report and patient-rated MADRS) [109].

### Conclusions

The observation of rapid, robust, and long-lasting effects of NMDAR antagonists such as ketamine and esketamine encourages further research on drugs targeting glutamatergic transmission [5, 8]. A growing number of studies support the use of memantine and minocycline in MDD and SZ [8, 53,

**Table 1** Mechanisms of action of drugs targeting glutamatergic transmission used in the treatment of major psychiatric disorders [3, 7, 41, 43, 58, 110, 111]

Substance /drug	Mechanisms of action related to glutamate	Other mechanisms of action	Most important adverse effects /clinical limitations	References
Valproic acid	<ul style="list-style-type: none"> <li>• ↓ excitatory glutamatergic transmission and ↑ inhibitory GABAergic transmission associated with the following mechanisms:               <ul style="list-style-type: none"> <li>• positive allosteric modulation GABA-A receptor</li> <li>• GABA transaminase inhibition → ↓ GABA degradation</li> <li>• ↑ activity of glutamate acid activity → ↑ glutamate degradation and ↑ glutamate to GABA conversion</li> <li>• inhibition of Na<sup>+</sup> channels and voltage-dependent Ca<sup>2+</sup> channels, resulting in inhibition of glutamate release</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• inhibition of histone deacetylases</li> <li>• non-competitive inhibition of microsomal acyl-CoA synthetase</li> <li>• inhibition of phosphatidylinositol cycle, e.g., by reducing MIPS activity</li> <li>• modulation of Ca<sup>2+</sup> channel activity of type T, type L, and type N,</li> <li>• ↓ activity of COX-1 and COX-2 within CNS</li> <li>• inhibition of mitochondrial dehydrogenases</li> <li>• regulation of cyclin-dependent kinase inhibitor 1</li> <li>• downregulation of programmed death receptor ligand 1 (PD-L1)</li> </ul>	<p>The most common side effects are increased appetite and body weight, dizziness, ataxia, drowsiness, fatigue, gastrointestinal symptoms, rash, tremors, hair loss</p> <p>Beware of the risk of:</p> <ul style="list-style-type: none"> <li>• hepatotoxicity</li> <li>• induction or worsening of metabolic syndrome symptoms</li> <li>• hematological disorders (including thrombocytopenia)</li> <li>• pancreatitis</li> </ul> <p>Administered to pregnant women may cause serious birth defects and an increased risk of neurodevelopmental disorders in children exposed to the drug in utero</p>	[3, 113–117]
Lamotrigine	<ul style="list-style-type: none"> <li>• inhibition of Na<sup>+</sup> channels and voltage-dependent Ca<sup>2+</sup> channels, resulting in inhibition of glutamate release</li> <li>• weak inhibition of AMPA IR</li> </ul>	<ul style="list-style-type: none"> <li>• ↓ neuronal excitability and firing frequency due to inhibition of Na<sup>+</sup> and Ca<sup>2+</sup> channels.</li> <li>• modulation of HCN channels (cyclic nucleotide-gated channels)</li> <li>• inhibition of pro-inflammatory microglial activity</li> <li>• interaction with the activity of numerous receptors in the CNS (the significance of these mechanisms is unclear) - including adenosine, 5HT<sub>3</sub>, 5HT<sub>2a</sub>, GABA-A, HA, kappa and many others</li> </ul>	<p>Generally well-tolerated</p> <p>The most common side effects observed in psychiatric studies: gastrointestinal symptoms, rash, dizziness, headache, memory or concentration problems, sedation</p> <p>Beware of the risk of Stevens-Johnson syndrome</p>	[3, 118–125]
Carbamazepine	<ul style="list-style-type: none"> <li>• inhibition of Na<sup>+</sup> channels and voltage-dependent Ca<sup>2+</sup> channels, resulting in inhibition of glutamate release</li> </ul>	<ul style="list-style-type: none"> <li>• ↓ neuronal excitability and firing frequency due to inhibition of Na<sup>+</sup> and Ca<sup>2+</sup> channels.</li> <li>• ↓ activity and production of AA-selective cPLA2</li> <li>• ↓ activity of cyclooxygenases in CNS</li> </ul>	<p>The most common side effects are: dizziness, ataxia, drowsiness, fatigue, gastrointestinal symptoms, rash</p> <p>Beware of the risk of</p> <ul style="list-style-type: none"> <li>• Hyponatremia</li> <li>• Neutropenia/agranulocytosis</li> <li>• Stevens-Johnson syndrome</li> <li>• Hepatotoxicity</li> </ul> <p>Risk of loss or reduced effectiveness of many drugs due to enzymatic induction (carbamazepine is an inducer of P-glycoprotein, CYP450 1A2, 2D6, 3A4, 2C9, 2C19)</p> <p>Administered to pregnant women may cause serious birth defects</p>	[121, 126, 127]

Table 1 (continued)

Substance /drug	Mechanisms of action related to glutamate	Other mechanisms of action	Most important adverse effects /clinical limitations	References
Topiramate	<ul style="list-style-type: none"> <li>• inhibition of Na<sup>+</sup> channels and voltage-dependent Ca<sup>2+</sup> channels, resulting in inhibition of glutamate release</li> <li>• antagonism against glutamatergic kainate receptors</li> </ul>	<ul style="list-style-type: none"> <li>• agonism against alpha1 subunit of GABA-A receptors</li> </ul>	<p>Paresthesia, taste perversion, upper respiratory tract infection, memory and concentration difficulties occurred significantly more frequently among the topiramate-treated participants than the placebo-treated subjects in studies of binge-eating disorder patients</p> <p>In schizophrenia patients studies Topiramate was associated with significantly more adverse drug reactions than the control condition, including concentration/attention difficulties, psychomotor slowing, and paresthesia</p> <p>An increased incidence of mood disorders and depression, cases of a syndrome consisting of sudden myopia and secondary angle-closure glaucoma and cases of hyperchloremic metabolic acidosis has been reported in patients taking topiramate</p> <p>Administered to pregnant women may cause serious birth defects and an increased risk of neurodevelopmental disorders in children exposed to the drug in utero</p>	[3, 128–134]
Ketamine /esketamine	<ul style="list-style-type: none"> <li>• noncompetitive NMDAR antagonism</li> </ul>	<ul style="list-style-type: none"> <li>• potentiation of 5HT<sub>3A</sub> receptors</li> <li>• antagonism of alpha-7 subunit of neuronal acetylcholine receptor</li> <li>• partial agonism of D<sub>2</sub> receptors</li> <li>• cholinesterase inhibitor</li> <li>• inhibitor of brain nitric oxide synthase</li> <li>• inhibition of norepinephrine transporter</li> </ul>	<p>Ketamine or esketamine intravenous administration is associated with short-lasting, reversible side effects during the 4 h after the infusion: drowsiness, dizziness, poor coordination, blurred vision, dissociative or depersonalization symptoms, anxiety, transient increases in pulse and mean blood pressure, nausea, and sedation.</p> <p>Studies involving nasal administration of esketamine have shown the following short-term and self-limiting side effects: nausea, dizziness, vomiting, vertigo, dysgeusia, lethargy, dysesthesia, increased blood pressure, sedation, dissociation symptoms.</p> <p>The drugs should not be used by patients for whom increased blood pressure or intracranial pressure pose a serious risk.</p> <p>There is a risk of drug abuse.</p>	[135–143]

Table 1 (continued)

Substance /drug	Mechanisms of action related to glutamate	Other mechanisms of action	Most important adverse effects /clinical limitations	References
Memantine	<ul style="list-style-type: none"> <li>• noncompetitive NMDAR (weak voltage-dependent activity with fast-off kinetics)</li> </ul>	<ul style="list-style-type: none"> <li>• Inhibition of glycine receptors</li> <li>• 5-HT<sub>3A</sub> antagonism</li> </ul>	<p>Generally well tolerated with no or minimal side effects</p> <p>Beware of the possibility of lowering the seizurethreshold</p>	[8, 144, 145]
Minoocycline	<ul style="list-style-type: none"> <li>• indirect inhibitory effect on excitotoxicity dependent on the NMDAR stimulation</li> <li>• modulation of the AMPAR and mGluRI activity</li> </ul>	<ul style="list-style-type: none"> <li>• indirect inhibitory effect on excitotoxicity dependent on the stimulation of NMDA receptors</li> <li>• modulation of the activity of glutamatergic AMPA receptors and metabotropic mGluRI receptors</li> <li>• Modulation of IL-1b activity</li> <li>• Inhibition of arachidonic 5-lipoxygenase</li> <li>• Inhibition of MMP-9</li> <li>• Negative modulation of caspases</li> <li>• D<sub>2</sub> and D<sub>1</sub> receptor agonism</li> <li>• antagonist towards neuronal receptor for acetylcholine</li> <li>• enhancing the release of dopamine and inhibiting its reuptake</li> <li>• inhibition of GSK-3</li> <li>• influence on the permeability of the blood-brain barrier.</li> <li>• influence on the activity of GPR39.</li> </ul>	<p>Generally well tolerated with side effect rate comparable to placebo</p> <p>The most frequent adverse events in minocycline groups were: gastrointestinal symptoms, flu-like symptoms, headache, and dizziness</p>	[40–44, 146, 147]
Amantadine	<ul style="list-style-type: none"> <li>• NMDAR antagonism</li> </ul>	<ul style="list-style-type: none"> <li>• D<sub>2</sub> and D<sub>1</sub> receptor agonism</li> <li>• antagonist towards neuronal receptor for acetylcholine</li> <li>• enhancing the release of dopamine and inhibiting its reuptake</li> </ul>	<p>No adverse effects were reported in depressive disorders add-on studies so far.</p> <p>Beware of the potential risk of QT prolongation and lowering the seizure threshold</p>	[83–85, 148, 149]
Zinc	<ul style="list-style-type: none"> <li>• NMDAR antagonism and modulation</li> <li>• mGluRI and mGluR2 antagonism</li> <li>• ↑ AMPAR activity</li> </ul>	<ul style="list-style-type: none"> <li>• inhibition of GSK-3</li> <li>• influence on the permeability of the blood-brain barrier.</li> <li>• influence on the activity of GPR39.</li> </ul>	<p>No adverse effects were reported in depressive disorder trials</p> <p>Long-term use of zinc salts may result in copper deficiency and anemia.</p> <p>Zinc is contraindicated in renal failure.</p>	[58, 63, 65, 150–153]
<i>Crocus sativus</i> extract	<ul style="list-style-type: none"> <li>• NMDAR antagonism</li> </ul>	<ul style="list-style-type: none"> <li>• sigma receptors antagonism</li> <li>• serotonin and noradrenaline reuptake inhibition</li> <li>• Interaction with GABA-A receptors?</li> <li>• Anti-inflammatory, anti-apoptotic, and oxidative stress-reducing effects.</li> <li>• MAO inhibition</li> </ul>	<p>Generally well tolerated</p> <p>The most common adverse effects reported in clinical trials for saffron supplementation were: headache, nausea, anxiety, and decreased appetite</p>	[66, 68, 69, 78]

**Table 1** (continued)

Substance /drug	Mechanisms of action related to glutamate	Other mechanisms of action	Most important adverse effects /clinical limitations	References
N-acetylcysteine	<ul style="list-style-type: none"> <li>• Cystine/glutamate transporter activator</li> <li>• Glutamate NMDA receptor subunits activator</li> </ul>	<ul style="list-style-type: none"> <li>• Inhibitor of nuclear factor kappa-B kinase - Modulation of inflammatory / antiinflammatory processes</li> </ul>	<p>Generally well tolerated</p> <p>The most common adverse effects reported in clinical trials in depression or BD: altered energy levels, headaches, increased joint pain, heartburn, sweating, gastrointestinal symptoms the drug requires caution or should not be used in people with active peptic ulcer disease, severe respiratory failure or asthma, and esophageal varices</p>	[100, 154–157]
Rapastinel	<ul style="list-style-type: none"> <li>• Agonist of NMDAR glycine site</li> </ul>		<p>Generally well tolerated</p> <p>Transient dizziness was reported in one trial</p>	[96, 98]
Basimglurant	<ul style="list-style-type: none"> <li>• Negative allosteric modulator of mGluR5</li> </ul>		<p>Generally well tolerated</p> <p>The most common adverse events in clinical trials in MDD were: dizziness, somnolence, headache</p>	[110]

*GABA* - gamma-aminobutyric acid, *PD-L1* - programmed cell death protein ligand 1, *CoA* - coenzyme A, *COX* - cyclooxygenase, *CNS* - central nervous system, *MIPS* - myo-inositol monophosphate, *AMPA* - alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, *NMDAR* - N-methyl-D-aspartic acid, *HCN* - hyperpolarization-activated cyclic nucleotide-gated channel, *cPLA2* - cytosolic phospholipase A2, *AA* - arachidonic acid, *mGluR* - metabotropic glutamate receptor, *D* - dopamine, *MAO* - monoamine oxidase

54]. Amantadine, zinc, and *Crocus sativus* extracts yield the potential to ameliorate depressive symptoms in patients with affective disorders [60, 72, 84, 85]. Drugs with mechanisms of action based on glutamate constitute a promising pharmacological group in the treatment of mental disorders that do not respond to standard methods of therapy [1]. Further research is needed on their efficacy, safety, dosage, interactions, and side effects, to determine their optimal clinical use. It is also important to highlight that unconventional drugs like minocycline, zinc, or *Crocus sativus* extracts exhibit a broad spectrum of mechanisms of action [40, 41, 45, 56, 60, 66, 71]. Although these substances interact with glutamate receptors, it is currently unclear to what extent the clinical effects of these drugs are dependent on their effects on the glutamatergic system. Future research should consider the potential of modulating glutamatergic transmission through interactions not only with glutamate receptors but also with its transporters. Dysfunctions of excitatory amino acid transporters (EAATs) are involved in the pathophysiology of various neuropsychiatric disorders such as SZ, Alzheimer's disease, autism spectrum disorder, or epilepsy [156–158]. EAAT2, the primary transporter responsible for glutamate clearance in the brain, is crucial for regulating glutamatergic transmission and preventing excitotoxicity [156]. There are ongoing studies that aim to identify novel positive allosteric modulators of EAAT2, which could offer innovative approaches for the development of therapies based on the enhancement of glutamate transport [156, 159]. Our review points out the crucial need for further research in the area of glutamatergic-based psychotropic drugs which could provide effective and safe alternatives.

**Author contributions** Both authors substantially contributed to the conception of the review, drafting the work and revising it critically, approved the final version and agreed to be accountable for all aspects of the publication.

**Funding** The study received no funding support.

**Data availability** No datasets were generated or analysed during the current study.

## Declarations

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will

need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Stachowicz K, Sowa-Kućma M. The treatment of depression — searching for new ideas. *Front Pharmacol*. 2022;13:4161. <https://doi.org/10.3389/FPHAR.2022.988648/BIBTEX>.
2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *Am J Psychiatry*. 2006;163:1905–17. <https://doi.org/10.1176/AJP.2006.163.11.1905>.
3. Siwek M. Dekalog Leczenia Depresji. Kompendium. Item Publishing, Warszawa. 2024. ISBN 978-83-67390-56-9.
4. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry*. 2006;163:28–40. <https://doi.org/10.1176/APPI.AJP.163.1.28>.
5. Pochwat B, Krupa AJ, Siwek M, Szewczyk B. New investigational agents for the treatment of major depressive disorder. *Expert Opin Investig Drugs*. 2022. <https://doi.org/10.1080/13543784.2022.2113376>.
6. Pitsikas N. Constituents of saffron (*Crocus sativus* L.) as potential candidates for the treatment of anxiety disorders and schizophrenia. *Molecules*. 2016. <https://doi.org/10.3390/molecules21030303>.
7. Siddiqui SA, Redha AA, Snoeck ER, Singh S, Simal-Gandara J, Ibrahim SA, et al. Anti-Depressant Properties of Crocin Molecules in Saffron. *Molecules*. 2022;27:2076. <https://doi.org/10.3390/MOLECULES27072076>.
8. Kikuchi T. Is Memantine Effective as an NMDA receptor antagonist in adjunctive therapy for Schizophrenia? *Biomolecules* 2020. Page 1134. 2020;10:10:1134. <https://doi.org/10.3390/BIOM10081134>.
9. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32:1362–74. <https://doi.org/10.1016/J.PNPBP.2008.01.008>.
10. Hassanpour F, Zarghami M, Mouodi S, Moosazadeh M, Barzegar F, Bagheri M, et al. Adjunctive memantine treatment of Schizophrenia: a Double-Blind, randomized placebo-controlled study. *J Clin Psychopharmacol*. 2019;39:634–8. <https://doi.org/10.1097/JCP.0000000000001115>.
11. Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. *Psychiatry Res*. 2019;282:112602. <https://doi.org/10.1016/J.PSYCHRES.2019.112602>.
12. Hsu TW, Chu CS, Ching PY, Chen GW, Pan CC. The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: a systematic review and updated meta-analysis of double-blind randomized controlled trials. *J Affect Disord*. 2022;306:182–9. <https://doi.org/10.1016/J.JAD.2022.03.047>.
13. Park M, Niciu MJ, Zarate CA. Novel glutamatergic treatments for severe Mood disorders. *Curr Behav Neurosci Rep*. 2015;2:198–208. <https://doi.org/10.1007/S40473-015-0050-5/FIGURES/2>.
14. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. *Nat Rev Drug Discov*. 2008;7:426–37. <https://doi.org/10.1038/nrd2462>.

15. Ulbrich MH, Isacoff EY. Rules of engagement for NMDA receptor subunits. *Proc Natl Acad Sci U S A*. 2008;105:14163–8. <https://doi.org/10.1073/PNAS.0802075105>.
16. Hansen KB, Yi F, Perszyk RE, Furukawa H, Wollmuth LP, Gibb AJ, et al. Structure, function, and allosteric modulation of NMDA receptors. *J Gen Physiol*. 2018;150:1081–105. <https://doi.org/10.1085/JGP.201812032>.
17. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. *Nat Rev Neurosci*. 2010;11(10):682–96. <https://doi.org/10.1038/nrn2911>.
18. Li CT, Yang KC, Lin WC. Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies. *Front Psychiatry*. 2018. <https://doi.org/10.3389/FPSYT.2018.00767>.
19. Kohtala S. Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. *Pharmacol Rep*. 2021;73:323–45. <https://doi.org/10.1007/S43440-021-00232-4>.
20. Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. *Curr Med Res Opin*. 2017;33:701–11. <https://doi.org/10.1080/03007995.2016.1277201>.
21. Phillips JL, Norris S, Talbot J, Hatchard T, Ortiz A, Birmingham M, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. *Neuropsychopharmacology*. 2020;45:606–12. <https://doi.org/10.1038/S41386-019-0570-X>.
22. Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoepfner B, et al. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. *J Affect Disord*. 2020;260:131–9. <https://doi.org/10.1016/J.JAD.2019.09.017>.
23. Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. *J Affect Disord*. 2020;264:527–34. <https://doi.org/10.1016/J.JAD.2019.11.086>.
24. Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. *Am J Psychiatry*. 2019;176:428–38.
25. Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to oral antidepressant therapy in treatment-resistant depression: a Randomized Clinical Trial. *JAMA Psychiatry*. 2018;75:139–48. <https://doi.org/10.1001/JAMAPSYCHIATRY.2017.3739>.
26. Floriano I, Silvinato A, Bernardo WM. The use of esketamine in the treatment of patients with oral antidepressant-resistant depression: systematic review and meta-analysis. *Rev Assoc Med Bras*. 2023. <https://doi.org/10.1590/1806-9282.2023D696>.
27. Johnson JW, Kotermanski SE. Mechanism of action of memantine. *Curr Opin Pharmacol*. 2006;6:61–7. <https://doi.org/10.1016/J.COPH.2005.09.007>.
28. Mishra SK, Hidau MK, Rai S. Memantine treatment exerts an antidepressant-like effect by preventing hippocampal mitochondrial dysfunction and memory impairment via upregulation of CREB/BDNF signaling in the rat model of chronic unpredictable stress-induced depression. *Neurochem Int*. 2021;142:104932. <https://doi.org/10.1016/J.NEUINT.2020.104932>.
29. Zhang J, Yao W, Hashimoto K. Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related Depression and potential therapeutic targets. *Curr Neuropharmacol*. 2016;14:721–31. <https://doi.org/10.2174/1570159X14666160119094646>.
30. Zheng W, Li XH, Yang XH, Cai DB, Ungvari GS, Ng CH, et al. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Psychol Med*. 2018;48:72–81. <https://doi.org/10.1017/S0033291717001271>.
31. Veerman SRT, Schulte PFJ, Smith JD, De Haan L. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. *Psychol Med*. 2016;46:1909–21. <https://doi.org/10.1017/S0033291716000398>.
32. Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Clozapine, but not haloperidol, enhances glial d-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. *Br J Pharmacol*. 2012;165:1543. <https://doi.org/10.1111/J.1476-5381.2011.01638.X>.
33. Yuen EY, Zhong P, Yan Z. Homeostatic regulation of glutamatergic transmission by dopamine D 4 receptors. *Proc Natl Acad Sci*. 2010;107:22308–13.
34. Joshi I, Yang YM, Wang LY. Coincident activation of Metabotropic Glutamate Receptors and NMDA receptors (NMDARs) Downregulates Perisynaptic/Extrasynaptic NMDARs and enhances high-fidelity neurotransmission at the developing Calyx of held synapse. *J Neurosci*. 2007;27:9989. <https://doi.org/10.1523/JNEUROSCI.2506-07.2007>.
35. Siwek M, Chrobak AA, Gorostowicz A, Król P, Dudek D. Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review. *Brain Sci*. 2023. <https://doi.org/10.3390/BRAINS113030445/S1>.
36. Siwek M, Chrobak AA, Gorostowicz A, Król P, Dudek D. Cariprazine augmentation of clozapine in schizophrenia—a retrospective chart review. *Front Pharmacol*. 2023;14:1321112. <https://doi.org/10.3389/FPHAR.2023.1321112/BIBTEX>.
37. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. *Psychopharmacology*. 2004;174:530–8. <https://doi.org/10.1007/s00213-004-1847-1>.
38. Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J, et al. Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. *Prog Neurobiol*. 2004;72:195–221. <https://doi.org/10.1016/J.PNEUROBIO.2004.02.004>.
39. Albelda N, Bar-On N, Joel D. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. *Psychopharmacology*. 2010;210:13–24. <https://doi.org/10.1007/S00213-010-1808-9>.
40. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. *Behav Brain Res*. 2009. <https://doi.org/10.1016/j.bbr.2008.09.040>.
41. Lu Y, Yang Y, Chen W, Du N, Du Y, Gu H, et al. Minocycline, but not doxycycline attenuates NMDA-induced [Ca<sup>2+</sup>]<sub>i</sub> and excitotoxicity. *NeuroReport*. 2021;32:38–43. <https://doi.org/10.1097/WNR.0000000000001558>.
42. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. *BMC Neurosci*. 2006. <https://doi.org/10.1186/1471-2202-7-56>.
43. Manev H, Manev R. Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS. *Amyotroph Lateral Scler*. 2009;10:416–7. <https://doi.org/10.3109/17482960802702288>.
44. Chu LS, Fang SH, Zhou Y, Yu GL, Wang ML, Zhang WP, et al. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. *Acta*

- Pharmacol Sin. 2007. <https://doi.org/10.1111/j.1745-7254.2007.00578.x>.
45. González JC, Egea J, Del Carmen Godino M, Fernandez-Gomez FJ, Sánchez-Prieto J, Gandía L, et al. Neuroprotectant minocycline depresses glutamatergic neurotransmission and ca(2+) signalling in hippocampal neurons. *Eur J Neurosci*. 2007;26:2481–95. <https://doi.org/10.1111/J.1460-9568.2007.05873.X>.
  46. Chaves C, Marque CR, Trzesniak C, Machado De Sousa JP, Zuardi AW, Crippa JAS, et al. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. *Braz J Med Biol Res*. 2009;42:1002–14. <https://doi.org/10.1590/S0100-879X2009001100002>.
  47. Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. *Psychopharmacology*. 2005;179:154–63. <https://doi.org/10.1007/S00213-004-2065-6/METRICS>.
  48. Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A, Rasoulinejad M, Zeinoddini A, Yalda A, et al. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. *Int Clin Psychopharmacol*. 2016;31:20–6. <https://doi.org/10.1097/YIC.000000000000098>.
  49. Dean OM, Kanchanatawan B, Ashton M, Mohebbi M, Ng CH, Maes M, et al. Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial. <http://DxDoi.Org/101177/0004867417709357>. 2017;51:829–40. <https://doi.org/10.1177/0004867417709357>.
  50. Husain MI, Chaudhry IB, Husain N, Khoso AB, Rahman RR, Hamirani MM, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. *J Psychopharm*. 2017;31:1166–75. <https://doi.org/10.1177/0269881117724352>.
  51. Hellmann-Regen J, Clemens V, Grözinger M, Kornhuber J, Reif A, Prvulovic D, et al. Effect of Minocycline on depressive symptoms in patients with treatment-resistant depression: a Randomized Clinical Trial. *JAMA Netw Open*. 2022;5:E2230367. <https://doi.org/10.1001/jamanetworkopen.2022.30367>.
  52. Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. *Neuropsychopharmacol* 2021. 2021;46:5. <https://doi.org/10.1038/s41386-020-00948-6>.
  53. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. *Clin Neuropharmacol*. 2008;31:287–92. <https://doi.org/10.1097/WNF.0B013E3181593D45>.
  54. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. *J Clin Psychiatry*. 2010;71:138–49. <https://doi.org/10.4088/JCP.08M04666YEL>.
  55. Takeda A. Movement of zinc and its functional significance in the brain. *Brain Res Rev*. 2000;34:137–48. [https://doi.org/10.1016/S0165-0173\(00\)00044-8](https://doi.org/10.1016/S0165-0173(00)00044-8).
  56. Szewczyk B. Zinc homeostasis and neurodegenerative disorders. *Front Aging Neurosci*. 2013;5:54272. <https://doi.org/10.3389/FNAGI.2013.00033/BIBTEX>.
  57. Takeda A. Insight into glutamate excitotoxicity from synaptic zinc homeostasis. *Int J Alzheimers Dis*. 2010. <https://doi.org/10.4061/2011/491597>.
  58. Siwek M, Szewczyk B, Dudek D, Styczeń K, Sowa-Kućma M, Młyniec K, et al. Zinc as a marker of affective disorders. *Pharmacol Rep*. 2013;65:1512–8. [https://doi.org/10.1016/S1734-1140\(13\)71512-3](https://doi.org/10.1016/S1734-1140(13)71512-3).
  59. Hermens DF, Simcock G, Dutton M, Bouças AP, Can AT, Lilliey C, et al. Anorexia nervosa, zinc deficiency and the glutamate system: the ketamine option. *Prog Neuropsychopharmacol Biol Psychiatry*. 2020;101:109921. <https://doi.org/10.1016/J.PNPBP.2020.109921>.
  60. Sowa-Kućma M, Legutko B, Szewczyk B, Novak K, Znojek P, Poleszak E, et al. Antidepressant-like activity of zinc: further behavioral and molecular evidence. *J Neural Transm*. 2008;115:1621–8. <https://doi.org/10.1007/s00702-008-0115-7>.
  61. Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative inflammatory pathways in depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35:693–701. <https://doi.org/10.1016/J.PNPBP.2010.02.010>.
  62. Swardfager W, Herrmann N, McIntyre RS, Mazereeuw G, Goldberger K, Cha DS, et al. Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. *Neurosci Biobehav Rev*. 2013;37:911–29. <https://doi.org/10.1016/J.NEUBIOREV.2013.03.018>.
  63. Siwek M, Dudek D, Paul IA, Sowa-Kućma M, Zieba A, Popik P, et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. *J Affect Disord*. 2009;118:187–95. <https://doi.org/10.1016/j.jad.2009.02.014>.
  64. DiGirolamo AM, Ramirez-Zea M, Wang M, Flores-Ayala R, Martorell R, Neufeld LM, et al. Randomized trial of the effect of zinc supplementation on the mental health of school-age children in Guatemala. *Am J Clin Nutr*. 2010;92:1241–50. <https://doi.org/10.3945/AJCN.2010.29686>.
  65. Ranjbar E, Shams J, Sabetkasaei M, M-Shirazi M, Rashidkhani B, Mostafavi A, et al. Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression. *Nutr Neurosci*. 2014;17:65–71. <https://doi.org/10.1179/1476830513Y.0000000066>.
  66. Midaoui A, El Ghzaïel I, Vervandier-Fasseur D, Ksila M, Zarrouk A, Nury T, et al. Saffron (*Crocus sativus* L.): A Source of Nutrients for Health and for the Treatment of Neuropsychiatric and Age-Related Diseases. *Nutrients*. 2022. <https://doi.org/10.3390/nu14030597>.
  67. Mazidi M, Shemshian M, Mousavi SH, Norouzy A, Kermani T, Moghiman T, et al. A double-blind, randomized and placebo-controlled trial of Saffron (*Crocus sativus* L.) in the treatment of anxiety and depression. *J Complement Integr Med*. 2016;13:195–9. <https://doi.org/10.1515/JCIM-2015-0043>.
  68. Hosseinzadeh H, Sadeghnia HR, Rahimi A. Effect of safranal on extracellular hippocampal levels of glutamate and aspartate during kainic acid treatment in anesthetized rats. *Planta Med*. 2008;74:1441–5. <https://doi.org/10.1055/S-2008-1081335>.
  69. Berger F, Hensel A, Nieber K. Saffron extract and trans-crocetin inhibit glutamatergic synaptic transmission in rat cortical brain slices. *Neuroscience*. 2011;180:238–47. <https://doi.org/10.1016/J.NEUROSCIENCE.2011.02.037>.
  70. Amin B, Nakhshab A, Hosseinzadeh H. Evaluation of the antidepressant-like effects of acute and sub-acute administration of crocin and crocetin in mice. *Avicenna J Phytomed*. 2015;5:458.
  71. Hosseinzadeh H, Karimi G, Niapoor M. Antidepressant effect of *Crocus sativus* L. stigma extracts and their constituents, crocin and safranal, in mice. *Acta Hort*. 2004;650:435–45. <https://doi.org/10.17660/ACTAHORTIC.2004.650.54>.
  72. Hausenblas HA, Saha D, Dubyak PJ. Saffron (*Crocus sativus* L.) and major depressive disorder: a meta-analysis of randomized clinical trials. *J Integr Med*. 2013;11:377–83. <https://doi.org/10.3736/jintegrmed2013056>.
  73. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of *Crocus sativus* L. and imipramine in the treatment of mild to moderate depression: a

- pilot double-blind randomized trial [ISRCTN45683816]. *BMC Complement Altern Med*. 2004;4:12. <https://doi.org/10.1186/1472-6882-4-12>.
74. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of *Crocus sativus* L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. *J Ethnopharmacol*. 2005;97:281–4. <https://doi.org/10.1016/J.JEP.2004.11.004>.
  75. Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: a randomised, double-blind, placebo-controlled study. *J Affect Disord*. 2017;207:188–96. <https://doi.org/10.1016/J.JAD.2016.09.047>.
  76. Ahmadian M, Ramezanshams F, Ghaleiha A, Akhondzadeh S, Sadeghi Bahmani D, Brand S. *Crocus Sativus* L. (saffron) versus sertraline on symptoms of depression among older people with major depressive disorders—a double-blind, randomized intervention study. *Psychiatry Res*. 2019. <https://doi.org/10.1016/J.PSYCHRES.2019.112613>.
  77. Ravindran AV, Balneaves LG, Faulkner G, Ortiz A, McIntosh D, Morehouse RL, et al. Canadian Network for Mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Sect. 5. Complementary and alternative medicine treatments. *Can J Psychiatry*. 2016;61:576–87. <https://doi.org/10.1177/0706743716660290>.
  78. Georgiadou G, Grivas V, Tarantilis PA, Pitsikas N. Crocins, the active constituents of *Crocus Sativus* L., counteracted ketamine-induced behavioural deficits in rats. *Psychopharmacology*. 2014;231:717–26. <https://doi.org/10.1007/S00213-013-3293-4>.
  79. Chrobak AA, Siuda K, Biela M, Arciszewska A, Siwek M, Pilecki MW, et al. Convergence insufficiency with unilateral exophoria at near in schizophrenia and bipolar disorder - a preliminary study. *Psychiatr Pol*. 2014;48:1143–54. <https://doi.org/10.12740/PP/28726>.
  80. Chrobak AA, Siuda-Krzywicka K, Sołtys Z, Siwek GP, Bohaterewicz B, Sobczak AM, et al. Relationship between neurological and cerebellar soft signs, and implicit motor learning in schizophrenia and bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2021. <https://doi.org/10.1016/j.pnpbp.2020.110137>.
  81. Fadai F, Mousavi B, Ashtari Z, Ali Beigi N, Farhang S, Hashempour S, et al. Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study. *Pharmacopsychiatry*. 2014;47:156–61. <https://doi.org/10.1055/s-0034-1382001>.
  82. Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R. Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. *Braz J Psychiatry*. 2018;40:449–58. <https://doi.org/10.1590/1516-4446-2017-2393>.
  83. Krzystanek M, Martyniak E, Pałasz A, Skalaćka K, Chwalba A, Wierzbński P. Amantadine in treatment of Dysthymia—the Pilot Case Series Study. *Pharmaceuticals*. 2023;16:1–10. <https://doi.org/10.3390/ph16060897>.
  84. Rogóż Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. *Pharmacol Rep*. 2007;59:778.
  85. Krzystanek M, Pałasz A. Possibility of a new indication for amantadine in the treatment of bipolar depression—case series study. *Pharmaceuticals*. 2020;13:1–10. <https://doi.org/10.3390/ph13100326>.
  86. Nikolaus S, Wittsack HJ, Beu M, Antke C, Hautzel H, Wickrath F, et al. Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity. *Pharmacol Biochem Behav*. 2019;179:156–70. <https://doi.org/10.1016/J.PBB.2018.12.010>.
  87. Lima T, de Visacri M, Aguiar MB. Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. *Eur J Clin Pharmacol*. 2022;78:311–38. <https://doi.org/10.1007/S00228-021-03216-8>.
  88. Morrow K, Choi S, Young K, Haidar M, Boduch C, Bourgeois JA. Amantadine for the treatment of childhood and adolescent psychiatric symptoms. *Proc (Bayl Univ Med Cent)*. 2021;34:566–70. <https://doi.org/10.1080/08998280.2021.1925827>.
  89. Muzina DJ, Elhaj O, Gajwani P, Gao K, Calabrese JR. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. *Acta Psychiatr Scand Suppl*. 2005;111:21–8. <https://doi.org/10.1111/J.1600-0447.2005.00523.X>.
  90. Grunze HCR. The effectiveness of anticonvulsants in psychiatric disorders. *Dialogues Clin Neurosci*. 2008;10:77. <https://doi.org/10.31887/DCNS.2008.10.1/HCRGRUNZE>.
  91. Boaventura V, Lyrio RR, Nardi AE, Cheniaux E. Carbamazepine in the treatment of bipolar disorder: a systematic review. *J Bras Psiquiatr*. 2023;72:247–55. <https://doi.org/10.1590/0047-2085000000434>.
  92. Yee CS, Vázquez GH, Hawken ER, Biorac A, Tondo L, Baldessarini RJ. Long-term treatment of bipolar disorder with Valproate: updated systematic review and Meta-analyses. *Harv Rev Psychiatry*. 2021;29:188–95. <https://doi.org/10.1097/HRP.000000000000292>.
  93. Goh KK, Chen CH, Chiu YH, Lu ML. Lamotrigine augmentation in treatment-resistant unipolar depression: a comprehensive meta-analysis of efficacy and safety. *J Psychopharmacol*. 2019;33:700–13. <https://doi.org/10.1177/0269881119844199>.
  94. Nouredine M, Jurek L, Auffret M, Iceta S, Grenet G, Kas-sai B, et al. Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis. *CNS Spectr*. 2021;26:459–67. <https://doi.org/10.1017/S1092852920001613>.
  95. Zheng W, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HFK, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. *Acta Psychiatr Scand*. 2016;134:385–98. <https://doi.org/10.1111/ACPS.12631>.
  96. Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM, et al. The development of Rapastinel (formerly GLYX-13); a Rapid Acting and Long lasting antidepressant. *Curr Neuropharmacol*. 2017;15:47. <https://doi.org/10.2174/1570159X14666160321122703>.
  97. Burgdorf J, Zhang XL, Weiss C, Gross A, Boikess SR, Kroes RA, et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. *Neuroscience*. 2015;308:202–11. <https://doi.org/10.1016/J.NEUROSCIEN.2015.09.004>.
  98. Preskorn S, Macaluso M, Mehra V, Zammit G, Moskal JR, Burch RM. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. *J Psychiatr Pract*. 2015;21:140–9. <https://doi.org/10.1097/01.PRA.0000462606.17725.93>.
  99. Henter ID, Park LT, Zarate CA. Novel glutamatergic modulators for the treatment of Mood disorders: current status. *CNS Drugs*. 2021;35:527. <https://doi.org/10.1007/S40263-021-00816-X>.
  100. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. *J Psychiatry Neurosci*. 2011;36:78. <https://doi.org/10.1503/JPN.100057>.
  101. Raghu G, Berk M, Campochiaro PA, Jaeschke H, Marenzi G, Richeldi L, et al. The multifaceted therapeutic role of N-Acetylcysteine (NAC) in disorders characterized by oxidative stress.

- Curr Neuropharmacol. 2020;19:1202–24. <https://doi.org/10.2174/1570159X19666201230144109>.
102. Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. *Biochim Biophys Acta*. 2013;1830:4117–29. <https://doi.org/10.1016/J.BBAGEN.2013.04.016>.
  103. Qian HR, Yang Y. Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). *Acta Pharmacol Sin*. 2009;30:907. <https://doi.org/10.1038/APS.2009.72>.
  104. Kishi T, Sakuma K, Hatano M, Iwata N. N-acetylcysteine for schizophrenia: a systematic review and meta-analysis. *Psychiatry Clin Neurosci*. 2023;77:119–21. <https://doi.org/10.1111/PCN.13502>.
  105. Pittas S, Theodoridis X, Haidich AB, Bozikas PV, Papazisis G. The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials. *Psychopharmacology*. 2021;238:1729–36. <https://doi.org/10.1007/S00213-021-05789-9/METRICS>.
  106. Kishi T, Miyake N, Okuya M, Sakuma K, Iwata N. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. *Psychopharmacology*. 2020;237:3481–7. <https://doi.org/10.1007/S00213-020-05629-2/METRICS>.
  107. Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, Von Kienlin M, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. *J Pharmacol Exp Ther*. 2015;353:213–33. <https://doi.org/10.1124/JPET.114.222463>.
  108. Fuxe K, Borroto-Escuela DO. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. *Expert Opin Investig Drugs*. 2015;24:1247–60. <https://doi.org/10.1517/13543784.2015.1074175>.
  109. Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Rabbia M, et al. Efficacy and safety of Basimglurant as adjunctive therapy for Major Depression: a Randomized Clinical Trial. *JAMA Psychiatry*. 2016;73:675–84. <https://doi.org/10.1001/JAMAPSYCHIATRY.2016.0838>.
  110. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res*. 2018;46:D1074–82. <https://doi.org/10.1093/NAR/GKX1037>.
  111. Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. *Nucleic Acids Res*. 2024;52:D1265–75. <https://doi.org/10.1093/NAR/GKAD976>.
  112. Szalowska E, Van Der Burg B, Man HY, Hendriksen PJM, Peijnenburg AACM. Model Steatogenic compounds (Amiodarone, Valproic Acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. *PLoS ONE*. 2014;9:e86795. <https://doi.org/10.1371/JOURNAL.PONE.0086795>.
  113. Farber NB, Jiang XP, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. *Mol Psychiatry*. 2002;7:726–33. <https://doi.org/10.1038/SJ.MP.4001087>.
  114. Bazinet RP, Weis MT, Rapoport SI, Rosenberger TA. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. *Psychopharmacology*. 2006;184:122–9. <https://doi.org/10.1007/S00213-005-0272-4>.
  115. Kawano T, Akiyama M, Agawa-Ohta M, Mikami-Terao Y, Iwase S, Yanagisawa T, et al. Histone deacetylase inhibitors valproic acid and decapeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. *Int J Oncol*. 2010;37:787–95. [https://doi.org/10.3892/IJO\\_00000728](https://doi.org/10.3892/IJO_00000728).
  116. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? *Cell Mol Life Sci*. 2007;64:2090–103. <https://doi.org/10.1007/S00018-007-7079-X>.
  117. Leng Y, Fessler EB, Chuang DM. Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: Roles of chromatin remodelling and Bcl-2 induction. *Int J Neuropsychopharmacol*. 2013. <https://doi.org/10.1017/S1461145712000429>.
  118. Kotwal A, Cutrona SL. Serotonin Syndrome in the Setting of Lamotrigine, Aripiprazole, and Cocaine Use. *Case Rep Med*. 2015. <https://doi.org/10.1155/2015/769531>.
  119. Chartoff EH, Connery HS. It's MORE exciting than mu: cross-talk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. *Front Pharmacol*. 2014. <https://doi.org/10.3389/fphar.2014.00116>.
  120. Vinod KY, Subhash MN. Lamotrigine induced selective changes in 5-HT1A receptor mediated response in rat brain. *Neurochem Int*. 2002. [https://doi.org/10.1016/S0197-0186\(01\)00088-2](https://doi.org/10.1016/S0197-0186(01)00088-2).
  121. Bourin M, Masse F, Hascoët M. Evidence for the activity of lamotrigine at 5-HT1A receptors in the mouse forced swimming test. *J Psychiatry Neurosci*. 2005;30:275.
  122. Braga MFM, Aroniadou-Anderjaska V, Post RM, Li H. Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: Implications for its effects in seizure and affective disorders - Lamotrigine and inhibition in the amygdala. *Neuropharmacology*. 2002. [https://doi.org/10.1016/S0028-3908\(01\)00198-8](https://doi.org/10.1016/S0028-3908(01)00198-8).
  123. Abelaira HM, Réus GZ, Ribeiro KF, Zappellini G, Cipriano AL, Scaini G, et al. Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats. *Pharmacol Biochem Behav*. 2012. <https://doi.org/10.1016/j.pbb.2012.01.019>.
  124. Dibué-Adjei M, Kamp MA, Alpdogan S, Tevoufouet EE, Neiss WF, Hescheler J, et al. Ca<sub>v</sub>2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine in Vivo. *Cell Physiol Biochem*. 2017. <https://doi.org/10.1159/000485361>.
  125. FDA Approved Drug Products. EQUETRO (carbamazepine) extended-release capsules – drug monograph n.d. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/021710s11s012tbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021710s11s012tbl.pdf) (accessed September 1, 2024).
  126. Lipkind GM, Fozzard HA. Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. *Mol Pharmacol*. 2010. <https://doi.org/10.1124/mol.110.064683>.
  127. Kuzmiski JB, Barr W, Zamponi GW, MacVicar BA. Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels. *Epilepsia*. 2005. <https://doi.org/10.1111/j.0013-9580.2005.35304.x>.
  128. Maryanoff BE. Phenotypic Assessment and the Discovery of Topiramate. *ACS Med Chem Lett*. 2016. <https://doi.org/10.1021/acsmchemlett.6b00176>.
  129. Braga MFM, Aroniadou-Anderjaska V, Li H, Rogawski MA. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. *J Pharmacol Exp Ther*. 2009. <https://doi.org/10.1124/jpet.109.153908>.
  130. FDA Approved Drug Products. Topamax (topiramate) for oral use- drug monograph: <https://www.accessdata.fda.gov/drugs>

- [atfda\\_docs/label/2017/020505s057\\_020844s0481bl.pdf](#) (accessed September 1, 2024).
131. Chung JY, Kim MW, Kim M. Efficacy of zonisamide in migraineurs with nonresponse to topiramate. *Biomed Res Int*. 2014. <https://doi.org/10.1155/2014/891348>.
  132. Garnett WR. Clinical pharmacology of topiramate: A review. *Epilepsia*. 2000. <https://doi.org/10.1111/j.1528-1157.2000.tb02174.x>.
  133. Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. *Neuropsychiatr Dis Treat*. 2006. <https://doi.org/10.2147/ndt.2006.2.4.475>.
  134. Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sánchez E, Gutiérrez-Rojas L, Meana JJ. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. *CNS Drugs*. 2018. <https://doi.org/10.1007/s40263-018-0519-3>.
  135. Spravato FDA. accessed September 1, label – product monograph: [https://s3-us-west-2.amazonaws.com/drugbank/cite\\_this/attachments/files/000/003/811/original/Spravato\\_FDA\\_label.pdf?1551895045](https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/003/811/original/Spravato_FDA_label.pdf?1551895045) (2024).
  136. Martin LL, Bouchal RL, Smith DJ. Ketamine inhibits serotonin uptake in vivo. *Neuropharmacology*. 1982. [https://doi.org/10.1016/0028-3908\(82\)90149-6](https://doi.org/10.1016/0028-3908(82)90149-6).
  137. Hustveit O, Maurset A, Øye I. Interaction of the Chiral Forms of Ketamine with Opioid, Phencyclidine,  $\sigma$  and Muscarinic Receptors. *Pharmacol Toxicol*. 1995. <https://doi.org/10.1111/j.1600-0773.1995.tb01041.x>.
  138. Seeman P, Guan HC, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. *Synapse*. 2009. <https://doi.org/10.1002/syn.20647>.
  139. Kohrs R, Durieux ME, Ketamine. Teaching an old drug new tricks. *Anesth Analg*. 1998. <https://doi.org/10.1097/00000539-199811000-00039>.
  140. Appadu BL, Lambert DG. Interaction of iv. anaesthetic agents with 5-HT<sub>3</sub> receptors. *Br J Anaesth*. 1996. <https://doi.org/10.1093/bja/76.2.271>.
  141. Sinner B, Graf BM. Ketamine. *Handb Exp Pharmacol*. 2008;182:313–33. [https://doi.org/10.1007/978-3-540-74806-9\\_15](https://doi.org/10.1007/978-3-540-74806-9_15).
  142. Salt PJ, Barnes PK, Beswick FJ. Inhibition of neuronal and extraneuronal uptake of noradrenaline by ketamine in the isolated perfused rat heart. *Br J Anaesth*. 1979;51:835–8. <https://doi.org/10.1093/BJA/51.9.835>.
  143. Memantine FDA. accessed September 1, label – drug monograph: [https://s3-us-west-2.amazonaws.com/drugbank/cite\\_this/attachments/files/000/004/396/original/Memantine\\_FDA\\_label.pdf?1555364061](https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/396/original/Memantine_FDA_label.pdf?1555364061) (2024).
  144. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. *CNS Drug Rev*. 2003. <https://doi.org/10.1111/j.1527-3458.2003.tb00254.x>.
  145. Steinmeyer J, Daufeldt S, Taiwo YO. Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. *Biochem Pharmacol*. 1998. [https://doi.org/10.1016/S0006-2952\(97\)00383-3](https://doi.org/10.1016/S0006-2952(97)00383-3).
  146. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. *Proc Natl Acad Sci*. 1996. <https://doi.org/10.1073/pnas.93.24.14014>.
  147. Hesselink MB, De Boer AG, Breimer DD, Danysz W. Adaptations of NMDA and dopamine D<sub>2</sub>, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists. *J Neural Transm*. 1999. <https://doi.org/10.1007/s007020050168>.
  148. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. *J Neurosci*. 2005. <https://doi.org/10.1523/JNEUROSCI.4262-04.2005>.
  149. Młyniec K, Trojan E, Ślusarczyk J, Głombik K, Basta-Kaim A, Budziszewska B, et al. Immune malfunction in the GPR39 zinc receptor of knockout mice: Its relationship to depressive disorder. *J Neuroimmunol*. 2016. <https://doi.org/10.1016/j.jneuroim.2015.12.001>.
  150. Siwek M, Dudek D, Schlegel-Zawadzka M, Morawska A, Piekoszewski W, Opoka W, et al. Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. *J Affect Disord*. 2010. <https://doi.org/10.1016/j.jad.2010.04.024>.
  151. Szewczyk B, Poleszak E, Sowa-Kućna M, Siwek M, Dudek D, Ryszewska-Pokraśniewicz B, et al. Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. *Pharmacol Rep*. 2008;60:588.
  152. Deepmala SJ, Kumar N, Delhey L, Berk M, Dean O, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. *Neurosci Biobehav Rev*. 2015;55:294–321. <https://doi.org/10.1016/j.neubiorev.2015.04.015>.
  153. Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A, et al. Cysteine regulation of protein function—as exemplified by NMDA-receptor modulation. *Trends Neurosci*. 2002;25:474–80. [https://doi.org/10.1016/S0166-2236\(02\)02245-2](https://doi.org/10.1016/S0166-2236(02)02245-2).
  154. Wright DJ, Gray LJ, Finkelstein DI, Crouch PJ, Pow D, Pang TY, et al. N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease. *Hum Mol Genet*. 2016;25:2923–33. <https://doi.org/10.1093/HMG/DDW144>.
  155. Oka SI, Kamata H, Kamata K, Yagisawa H, Hirata H. N-Acetylcysteine suppresses TNF-induced NF- $\kappa$ B activation through inhibition of I $\kappa$ B kinases. *FEBS Lett*. 2000;472:196–202. [https://doi.org/10.1016/S0014-5793\(00\)01464-2](https://doi.org/10.1016/S0014-5793(00)01464-2).
  156. Kortagere S, Mortensen OV, Xia J, Lester W, Fang Y, Srikanth Y, et al. Identification of Novel Allosteric modulators of Glutamate Transporter EAAT2. *ACS Chem Neurosci*. 2018;9:522–34.
  157. McGrath T, Baskerville R, Rogero M, Castell L. Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases. *Nutrients*. 2022. <https://doi.org/10.3390/NU14050917>.
  158. Chrobak AA, Soltys Z, Bergmann Glia L-T. Depression, and Autism Spectrum Disorder. *Mol Neurobiol*. 2017;54:1156–66. <https://doi.org/10.1007/s12035-016-9719-3>.
  159. Falcucci RM, Wertz R, Green JL, Meucci O, Salvino J, Fontana ACK. Novel positive allosteric modulators of glutamate transport have neuroprotective properties in an in vitro excitotoxic model. *ACS Chem Neurosci*. 2019;10:3437. <https://doi.org/10.1021/ACSCHMNEURO.9B00061>.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.